Evidence map›Paper›PMID 22260418›Full record

ArticleJournal of neuroinflammation2012

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.

Sven Jarius, Klemens Ruprecht, Brigitte Wildemann, Tania Kuempfel, Marius Ringelstein, Christian Geis, Ingo Kleiter, Christoph Kleinschnitz, Achim Berthele, Johannes Brettschneider and 39 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of neuroinflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 334 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
334citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

334 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

274 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

Sven JariusDivision of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Klemens Ruprecht
Brigitte Wildemann
Tania Kuempfel
Marius Ringelstein
Christian Geis
Ingo Kleiter
Christoph Kleinschnitz
Achim Berthele
Johannes Brettschneider
Kerstin Hellwig
Bernhard Hemmer
Ralf A Linker
Florian Lauda
Christoph A Mayer
Hayrettin Tumani
Arthur Melms
Corinna Trebst
Martin Stangel
Martin Marziniak
Frank Hoffmann
Sven Schippling
Jürgen H Faiss
Oliver Neuhaus
Barbara Ettrich
Christian Zentner
Kersten Guthke
Ulrich Hofstadt-van Oy
Reinhard Reuss
Hannah Pellkofer
Ulf Ziemann
Peter Kern
Klaus P Wandinger
Florian Then Bergh
Tobias Boettcher
Stefan Langel
Martin Liebetrau
Paulus S Rommer
Sabine Niehaus
Christoph Münch
Alexander Winkelmann
Uwe K Zettl U
Imke Metz
Christian Veauthier
Jörn P Sieb
Christian Wilke
Hans P Hartung
Orhan Aktas
Friedemann Paul

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity.

objectiveTo analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus.

methodsRetrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%).

resultsSeropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome.

conclusionThis study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodiesAquaporin 4Brain StemCohort StudiesDisability EvaluationFemaleHumansMagnetic Resonance ImagingMaleMethylprednisoloneMiddle AgedNeuromyelitis OpticaAntibodiesAQP4 protein, humanAquaporin 4MethylprednisoloneOligoclonal Bands

Identifiers

PMID22260418
PMCPMC3283476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.